PT - JOURNAL ARTICLE AU - Hyun ah Yoon AU - Rachel Bartash AU - Inessa Gendlina AU - Johanna Rivera AU - Antonio Nakouzi AU - Robert H. Bortz III AU - Ariel S. Wirchnianski AU - Monika Paroder AU - Karen Fehn AU - Leana Serrano-Rahman AU - Rachelle Babb AU - Uzma N. Sarwar AU - Denise Haslwanter AU - Ethan Laudermilch AU - Catalina Florez AU - M. Eugenia Dieterle AU - Rohit K. Jangra AU - J. Maximilian Fels AU - Karen Tong AU - Margarette C. Mariano AU - Olivia Vergnolle AU - George I. Georgiev AU - Natalia G. Herrera AU - Ryan J. Malonis AU - Jose A. Quiroz AU - Nicholas C. Morano AU - Gregory J. Krause AU - Joseph M. Sweeney AU - Kelsie Cowman AU - Stephanie Allen AU - Jayabhargav Annam AU - Ariella Applebaum AU - Daniel Barboto AU - Ahmed Khokhar AU - Brianna J. Lally AU - Audrey Lee AU - Max Lee AU - Avinash Malaviya AU - Reise Sample AU - Xiuyi A. Yang AU - Yang Li AU - Rafael Ruiz AU - Raja Thota AU - Jason Barnhill AU - Doctor Y. Goldstein AU - Joan Uehlinger AU - Scott J. Garforth AU - Steven C. Almo AU - Jonathan R. Lai AU - Morayma Reyes Gil AU - Amy S. Fox AU - Kartik Chandran AU - Tao Wang AU - Johanna P. Daily AU - Liise-anne Pirofski TI - Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC AID - 10.1101/2020.12.02.20242909 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.02.20242909 4099 - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242909.short 4100 - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242909.full AB - Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200mL of CCP with a Spike protein IgG titer ≥1:2,430 (median 1:47,385) within 72 hours of admission to propensity score-matched controls cared for at a medical center in the Bronx, between April 13 to May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroids, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared to matched controls, CCP recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28. For CCP recipients, pre-transfusion Spike protein IgG, IgM and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients <65 years, but data from controlled trials is needed to validate this finding and establish the effect of ageing on CCP efficacy.Competing Interest StatementKC is a member of the Scientific Advisory Board of Integrum Scientific, LLC. In addition, KC has a SARS-CoV-2 spike neutralization assay patent pending, and a SARS-CoV-2 spike antibody assay patent pending. JL reports grants from Adimab LLC, grants from Integrated BioTherapeutics, grants from Mapp Biopharmaceutical, personal fees from Johnson & Johnson, personal fees from Celdara Medical. In addition, JL has a COVID-19 antibody diagnostic patent pending. Other authors have declared that no conflict of interest exists.Funding StatementHY was supported by NIH/National Center for Advancing Translational Service (NCATS) Einstein-Montefiore CTSA Grant Number UL1TR001073. LP was supported in part by NIH grants AI 123664, AI 143453, NCATS 3UL1TR002556-04S1 and a grant from the Mathers Foundation. KC was supported in part by NIH grants U19AI142777 and R01AI32633 and a COVID-19 Pilot Award from Albert Einstein College of Medicine. JRL was supported by the NIH (R01-AI125462) and a COVID-19 Pilot Award from Albert Einstein College of Medicine. SCA was supported by R01AI145024, the Wollowick Family Foundation Chair in Multiple Sclerosis and Immunology, and Janet & Martin Spatz and the Helen & Irving Spatz Foundation. Additional support provided by the Albert Einstein Macromolecular Therapeutics Development Facility, the Einstein-Rockefeller-CUNY Center for AIDS Research (P30AI124414), and the Albert Einstein Cancer Center (P30CA013330). JPD was supported by NIAID R21AI141367. MCM and GIG were supported by an NIH Training Program in Cellular and Molecular Biology and Genetics (T32-GM007491). KT, JAQ, RJM, RHBIII and GK were supported by an NIH Medical Scientist Training Program (T32 GM007288) at Albert Einstein College of Medicine. This study was supported in part by a US Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) grant contract 75A50120C00096, National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octopharma USA, Inc, and the Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The retrospective cohort study, the donor plasma procurement protocol and the use of the expanded access protocol was approved by the Albert Einstein College of Medicine Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.